UHMB Cross-Bay VTE Audit 2022

Background and Aims

Methodology and Standards

first dose administered within 14 hours of admission

100% of patients had VTE prophylaxis/management reviewed on the first consultant review Additional areas were reviewed after discussion in audit meetings in previous cycles: Patent's’ receipt of verbal and written information about thromboprophyalxis If patients were to be discharged on extended VTE prophylaxis with low molecular weight heparin, was appropriate information and training given? If the patient was SARS-CoV-2 positive, was the modified regimen for thromboprophylaxis given?

Results (October 2022 cycle)

65% compliance of

Action Plan

Conclusions

Clear improvement has been demonstrated in compliance against NICE and local guidelines.

However we have room for improvement in administration of enoxaparin within 14 hours of admission, PTWR/consultant review of VTE prophylaxis, and provision of verbal and written patient information regarding VTE